Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC

INTRODUCTION: Checkpoint inhibitor pneumonitis (CIP) is a serious toxicity of anti–programmed death-(ligand) 1 immunotherapy. Whether pretreatment differences in pulmonary function exist in patients who develop CIP is unknown. We analyzed the pulmonary function tests (PFTs) of patients with NSCLC tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Reuss, Joshua E., Brigham, Emily, Psoter, Kevin J., Voong, Khinh Ranh, Shankar, Bairavi, Ettinger, David S., Marrone, Kristen A., Hann, Christine L., Levy, Benjamin, Feliciano, Josephine L., Brahmer, Julie R., Feller-Kopman, David, Lerner, Andrew D., Lee, Hans, Yarmus, Lonny, Hales, Russell K., D’Alessio, Franco, Danoff, Sonye K., Forde, Patrick M., Suresh, Karthik, Naidoo, Jarushka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552105/
https://www.ncbi.nlm.nih.gov/pubmed/34746881
http://dx.doi.org/10.1016/j.jtocrr.2021.100220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552105/
https://www.ncbi.nlm.nih.gov/pubmed/34746881
http://dx.doi.org/10.1016/j.jtocrr.2021.100220

Ejemplares similares